Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

被引：0
|
作者：
Hannelore Denys
Corina L. Martinez-Mena
Marc T. Martens
Randal G. D’Hondt
Marie-Pascale L. Graas
Ella Evron
Georgeta Fried
Noa E. Ben-Baruch
Christof Vulsteke
Mona M. Van Steenberghe
机构：
[1] UZ Gent,Integrated Cancer Center Ghent
[2] CHU St Pierre,Center for Oncological Research (CORE)
[3] AZ Turnhout,undefined
[4] AZ Damiaan,undefined
[5] CHC - Clinique Saint-Joseph,undefined
[6] Assaf Harofeh Medical Center,undefined
[7] Rambam Medical Center,undefined
[8] Kaplan Medical Center,undefined
[9] AZ Maria Middelares,undefined
[10] Antwerp University,undefined
[11] Roche nv/sa,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 181卷
关键词：
Safety; Tolerability; Subcutaneous trastuzumab; HER2-positive early breast cancer; At home administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 105
页数：8
相关论文
共 50 条
  • [21] 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
    Gianni, Luca
    Pienkowski, Tadeusz
    Im, Young-Hyuck
    Tseng, Ling-Ming
    Liu, Mei-Ching
    Lluch, Ana
    Staroslawska, Elzbieta
    de la Haba-Rodriguez, Juan
    Im, Seock-Ah
    Pedrini, Jose Luiz
    Poirier, Brigitte
    Morandi, Paolo
    Semiglazov, Vladimir
    Srimuninnimit, Vichien
    Bianchi, Giulia Valeria
    Magazzu, Domenico
    McNally, Virginia
    Douthwaite, Hannah
    Ross, Graham
    Valagussa, Pinuccia
    LANCET ONCOLOGY, 2016, 17 (06) : 791 - 800
  • [22] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [23] Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer
    Yamamoto, Harukaze
    Ando, Masashi
    Aogi, Kenjiro
    Iwata, Hiroji
    Tamura, Kenji
    Yonemori, Kan
    Shimizu, Chikako
    Hara, Fumikata
    Takabatake, Daisuke
    Hattori, Masaya
    Asakawa, Takashi
    Fujiwara, Yasuhiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 12 - 18
  • [24] Phase I Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer
    Nakayama, Takahiro
    Morita, Satoshi
    Takashima, Tsutomu
    Kamigaki, Shunji
    Yoshidome, Katsuhide
    Ito, Toshikazu
    Taguchi, Tetsuya
    Sakamoto, Junichi
    Noguchi, Shinzaburo
    ANTICANCER RESEARCH, 2011, 31 (09) : 3035 - 3039
  • [25] Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
    Tolaney, Sara M.
    Wardley, Andrew M.
    Zambelli, Stefania
    Hilton, John F.
    Troso-Sandoval, Tiffany A.
    Ricci, Francesco
    Im, Seock-Ah
    Kim, Sung-Bae
    Johnston, Stephen R. D.
    Chan, Arlene
    Goel, Shom
    Catron, Kristen
    Chapman, Sonya C.
    Price, Gregory L.
    Yang, Zhengyu
    Gainford, M. Corona
    Andre, Fabrice
    LANCET ONCOLOGY, 2020, 21 (06) : 763 - 775
  • [26] Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)
    Ciruelos, Eva M.
    Montano, Alvaro
    Rodriguez, Cesar A.
    Gonzalez-Flores, Encarnacion
    Lluch, Ana
    Garrigos, Laia
    Quiroga, Vanesa
    Anton, Antonio
    Malon, Diego
    Chacon, Jose, I
    Velasco, Montserrat
    Gonzalez-Cortijo, Lucia
    Jolis, Laura
    Echarri, Maria J.
    Munoz, Montse
    Pascual, Tomas
    Amigo, Yolanda
    Casas, Maribel
    Carrasco, Eva
    Casas, Ana
    EUROPEAN JOURNAL OF CANCER CARE, 2020, 29 (04)
  • [27] Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
    Simoens, Steven
    Vulto, Arnold G.
    Dylst, Pieter
    PHARMACEUTICALS, 2021, 14 (05)
  • [28] Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference-Substudy of the randomised phase III GAIN-2 study
    Reinisch, Mattea
    Untch, Michael
    Mahlberg, Rolf
    Reimer, Toralf
    Hitschold, Thomas
    Marme, Frederik
    Aydogdu, Mustafa
    Schmatloch, Sabine
    Lueck, Hans-Joachim
    Schmidt, Marcus
    Ladda, Ekkehart
    Sinn, Bruno Valentin
    Klare, Peter
    Janni, Wolfgang
    Jackisch, Christian
    Denkert, Carsten
    Seiler, Sabine
    Goehler, Thomas
    Michel, Laura
    Burchardi, Nicole
    Stickeler, Elmar
    Rey, Julia
    Klutinus, Nicole
    Moebus, Volker
    Loibl, Sibylle
    BREAST, 2022, 66 : 110 - 117
  • [29] Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer: A Review of Clinical Data With Nursing Implications
    Palmieri, Frances M.
    Myatt, Charlyn V.
    Perez, Edith A.
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (03) : 326 - 336
  • [30] RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
    Moreno-Aspitia, Alvaro
    Dueck, Amylou C.
    Ghanem-Canete, Ismael
    Patel, Tejal
    Dakhil, Shaker
    Johnson, David
    Franco, Sandra
    Kahanic, Stephen
    Colon-Otero, Gerardo
    Tenner, Kathleen S.
    Rodeheffer, Richard
    McCullough, Ann E.
    Jenkins, Robert B.
    Palmieri, Frances M.
    Northfelt, Donald
    Perez, Edith A.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (02) : 427 - 435
12345